ASNRT — Arab Society of Nephrology and Renal Transplantation

Finerenone in Type 1 Diabetes and Chronic Kidney Disease.

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD). The efficacy and safety of finerenone in persons with type 1 diabetes and CKD are unknown.

Category

Research

Source

N Engl J Med

Read the full abstract on PubMed

More from ASNRT News

Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.

All news · ASNRT home